Post COVID-19 pandemic recovery of intracity human mobility in Wuhan: Spatiotemporal characteristic and driving mechanism.

After successfully inhibiting the first wave of COVID-19 transmission through a city lockdown, Wuhan implemented a series of policies to gradually lift restrictions and restore daily activities. Existing studies mainly focus on the intercity recovery under a macroscopic view. How does the intracity mobility return to normal? Is the recovery process consistent among different subareas, and what factor affects the post-pandemic recovery? To answer these questions, we sorted out policies adopted during the Wuhan resumption, and collected the long-time mobility big data in 1105 traffic analysis zones (TAZs) to construct an observation matrix (A). We then used the nonnegative matrix factorization (NMF) method to approximate A as the product of two condensed matrices (WH). The column vectors of W matrix were visualized as five typical recovery curves to reveal the temporal change. The row vectors of H matrix were visualized to identify the spatial distribution of each recovery type, and were analyzed with variables of population, GDP, land use, and key facility to explain the recovery driving mechanisms. We found that the "staggered time" policies implemented in Wuhan effectively staggered the peak mobility of several recovery types ("staggered peak"). Besides, different TAZs had heterogeneous response intensities to these policies ("staggered area") which were closely related to land uses and key facilities. The creative policies taken by Wuhan highlight the wisdom of public health crisis management, and could provide an empirical reference for the adjustment of post-pandemic intervention measures in other cities.

Quantifying COVID-19 recovery process from a human mobility perspective: An intra-city study in Wuhan.

The COVID-19 pandemic has brought huge challenges to sustainable urban and community development. Although some recovery signals and patterns have been uncovered, the intra-city recovery process remains underexploited. This study proposes a comprehensive approach to quantify COVID-19 recovery leveraging fine-grained human mobility records. Taking Wuhan, a typical COVID-19 affected megacity in China, as the study area, we identify accurate recovery phases and select appropriate recovery functions in a data-driven manner. We observe that recovery characteristics regarding duration, amplitude, and velocity exhibit notable differences among urban blocks. We also notice that the recovery process under a one-wave outbreak lasts at least 84 days and has an S-shaped form best fitted with four-parameter Logistic functions. More than half of the recovery variance can be well explained and estimated by common variables from auxiliary data, including population, economic level, and built environments. Our study serves as a valuable reference that supports data-driven recovery quantification for COVID-19 and other crises.

Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.

Subunit influenza vaccine only formulated with surface antigen proteins has better safety profiles relative to split-virion influenza vaccine. Compared to the traditional quadrivalent split-virion influenza vaccine, a novel quadrivalent subunit influenza vaccine is urgently needed in China. We completed a phase 3, randomized, double-blind, active-controlled, non-inferiority clinical study at two sites in Henan Province, China. Eligible volunteers were split into four age cohorts (3-8 years, 9-17 years, 18-64 years, and ≥ 65 years, based on their dates of birth) and randomly assigned (1:1) to the subunit and the split-virion ecNAIIV4 groups. All volunteers were intramuscularly administered a single vaccine dose at baseline, and children aged 3-8 years received a boosting dose at day 28. And the immune response was evaluated by measuring hemagglutinin-inhibition antibody titers against the four vaccine strains in blood samples. Safety profiles had nonsignificant differences between the study groups in ≥ 3 years cohort. Most adverse reactions post-vaccination, both local and systemic, were mild to moderate and resolved within 3 days. And no serious adverse events occurred. The immunogenicity of the trial vaccine was non-inferior to the comparator. Further, a two-dose vaccine series can provide better seroprotection than that of a one-dose series in children aged 3-8 years, with clinically acceptable safety profiles. Clinical Trials Registration. ChiCTR2100049934.